SVA — Sernova Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$62.41m
- CA$61.75m
Annual income statement for Sernova Biotherapeutics, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 5.26 | 6.94 | 24.8 | 40.5 | 31.7 |
| Operating Profit | -5.26 | -6.94 | -24.8 | -40.5 | -31.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.32 | -6.97 | -24.4 | -39 | -32.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.32 | -6.97 | -24.4 | -39 | -32.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.32 | -6.97 | -24.4 | -39 | -32.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.32 | -6.97 | -24.4 | -39 | -32.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.027 | -0.028 | -0.089 | -0.129 | -0.105 |